Ivanović Vesna, Demajo Miroslav, Krtolica Koviljka, Krajnović Milena, Konstantinović Miroslav, Baltić Vladimir, Prtenjak Gordana, Stojiljković Bratislav, Breberina Milan, Nesković-Konstantinović Zora, Nikolić-Vukosavljević Dragica, Dimitrijević Bogomir
Clin Chim Acta. 2006 Sep;371(1-2):191-3. doi: 10.1016/j.cca.2006.02.027. Epub 2006 Feb 28.
The role of circulating TGF-beta(1) in prognosis of breast cancer (BC) was investigated with an intention to define TGF-beta(1)-dependent high risk and low risk subsets of patients.
Fifty three BC patients of all clinical stages and 37 healthy donors (HD) were analyzed for plasma TGF-beta(1) by the TbetaRII receptor-based Quantikine TGF-beta(1) ELISA kit.
The plasma TGF-beta(1) level of Stage I/II disease (median: 0.94 ng/ml; n=10)) remained close to HD (median: 1.30 ng/ml; n=37; p>0.1). In contrast, Stage III/IV disease (median: 2.34 ng/ml; n=43) exhibited highly significant TGF-beta(1) elevation (p<0.001) relative to HD. Further analysis revealed that TGF-beta(1) increase was predominantly attributed to Stage IV, metastatic disease patients (Q3=4.23 ng/ml) rather than to the group Stage III/IV (Q3=3.58 ng/ml). Using the plasma TGF-beta(1) concentration of 3.00 ng/ml as the cut-off value, two subgroups of patients were formed. Overall 2-year survival of the first subgroup, having elevated plasma TGF-beta(1) (>3.00 ng/ml; n=10), was 10%. This was significantly decreased (p<0.05) compared to 52% survival observed for the second subgroup of patients with plasma TGFbeta(1) values close to HD (<3.00 ng/ml, n=19).
We have performed a pilot study to determine the relationship between overall survival and TGF-beta(1) concentration in the blood of metastatic breast cancer patients. The survival was significantly reduced in the patients with elevated plasma TGF-beta(1) levels compared to that of the patients with plasma TGF-beta(1) levels close to normal. We propose that plasma TGF-beta(1) concentration may be a new tumour marker attributed to the presence of metastatic BC cells that may be used in selection of metastatic BC patients with poor prognosis.
研究循环中的转化生长因子β1（TGF-β1）在乳腺癌（BC）预后中的作用，旨在确定依赖TGF-β1的高风险和低风险患者亚组。
采用基于TbetaRII受体的Quantikine TGF-β1 ELISA试剂盒，对53例各临床分期的BC患者和37名健康供体（HD）的血浆TGF-β1进行分析。
I/II期疾病患者的血浆TGF-β1水平（中位数：0.94 ng/ml；n = 10）与HD相近（中位数：1.30 ng/ml；n = 37；p>0.1）。相比之下，III/IV期疾病患者（中位数：2.34 ng/ml；n = 43）的TGF-β1水平相对于HD显著升高（p<0.001）。进一步分析表明，TGF-β1升高主要归因于IV期转移性疾病患者（第三四分位数=4.23 ng/ml），而非III/IV期组（第三四分位数=3.58 ng/ml）。以血浆TGF-β1浓度3.00 ng/ml为临界值，形成了两个患者亚组。血浆TGF-β1升高（>3.00 ng/ml；n = 10）的第一亚组患者的总体2年生存率为10%。与血浆TGF-β1值接近HD（<3.00 ng/ml，n = 19）的第二亚组患者52%的生存率相比，该生存率显著降低（p<0.05）。
我们进行了一项初步研究，以确定转移性乳腺癌患者的总生存率与血液中TGF-β1浓度之间的关系。与血浆TGF-β1水平接近正常的患者相比，血浆TGF-β1水平升高的患者生存率显著降低。我们认为，血浆TGF-β1浓度可能是一种新的肿瘤标志物，与转移性BC细胞的存在有关，可用于筛选预后不良的转移性BC患者。
